18.20
+16.47(+952.02%)
Currency In USD
Address
18575 Jamboree Road
Irvine, CA 92612
United States of America
Phone
619 733 3852
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
April 08, 2021
| Name | Title | Pay | Year Born |
| Mr. Gregory J. Flesher | President, Chief Executive Officer & Director | 569,704 | 1970 |
| Mr. Michael G. Grey | Founder & Executive Chairman | 100,000 | 1953 |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466,229 | 1961 |
| Mr. Michael P. Cruse | Chief Operating Officer | 535,474 | 1972 |
| Ms. Jennifer P. Lam | SVice President of Finance & Administration and Principal Financial & Accounting Officer | 0 | N/A |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.